Pharma

Your Article Summary

See Latest Articles

Manufacturing a rapid biologic response
Drug Development Research, 06/19/09

Latham PW - Unfortunately, this kind of stockpiling is very expensive, and does not provide protection against novel threats. Fortunately, there currently exist many new technologies that, when combined strategically, have the potential to significantly reduce the time and cost associated with the PD and manufacturing of biologic countermeasures.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche, 12/14/09

Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche, 12/14/09

ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium
ImmunoGen, Inc., 12/14/09

 See all of Research & Development